Hookipa Pharma Gets $5 Million Milestone Payment From Gilead Sciences

By Chris Wack

Hookipa Pharma Inc. said Wednesday that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with Gilead Sciences Inc.

The company said it completed and delivered a regulatory support package for Gilead's Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using Hookipa's arenaviral platform.

Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate. Hookipa is eligible to receive milestone payments based on the achievement of specified development, regulatory and commercial milestones up to a total of more than $190 million, and is also eligible to receive tiered royalties on net sales.

Hookipa shares were up 7% at 86 cents a share in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 04, 2023 07:38 ET (12:38 GMT)

HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024